TG-43U1 Parameterization of Elongated RadioCoil 103Pd Brachytherapy Sources

Overview

Journal J Appl Clin Med Phys

Specialties Biophysics
General Medicine

Date 2007 Aug 23

PMID 17712301

Citations 3

Authors

Sharifeh A Dini

Shahid B Awan

Kai Dou

Ali S Meigooni

Affiliations

Soon will be listed here.

Abstract

Recently, to eliminate problems associated with seed type sources, RadioMed Corporation (Tyngsboro, MA) introduced RadioCoil 103Pd sources for interstitial prostate implants. The RadioCoil sources are available in integral lengths ranging from 1.0 cm to 6.0 cm. In this project, dosimetric characteristics of these sources were determined following the TG-43U1 recommendations, with consideration of our recent publication on the evaluation of two-dimensional anisotropy function for elongated brachytherapy sources. Dosimetric parameters of these sources were determined experimentally in Solid Water (Gammex RMI, Middleton, WI) and theoretically using Monte Carlo simulation in Solid Water and liquid water. Per the TG-43U1 protocol, the consensus of these results would be used for their clinical applications.

Citing Articles

Evaluation of hypothetical (153)Gd source for use in brachytherapy.

Ghorbani M, Behmadi M Rep Pract Oncol Radiother. 2016; 21(1):17-24.

PMID: 26900353 PMC: 4716406. DOI: 10.1016/j.rpor.2015.05.005.

Thermoluminescent and Monte Carlo dosimetry of IR06-103Pd brachytherapy source.

Saidi P, Sadeghi M, Hosseini S, Tenreiro C J Appl Clin Med Phys. 2011; 12(4):3581.

PMID: 22089014 PMC: 5718737. DOI: 10.1120/jacmp.v12i4.3581.

Cylindrical coordinate based TG-43U1 parameters for dose calculation around elongated brachytherapy sources.

Awan S, Dini S, Hussain M, Soleimani-Meigooni D, S Meigooni A J Appl Clin Med Phys. 2008; 9(2):123-142.

PMID: 18714281 PMC: 5721703. DOI: 10.1120/jacmp.v9i2.2760.

References

Seltzer S, Lamperti P, Loevinger R, Mitch M, Weaver J, Coursey B . New National Air-Kerma-Strength Standards for (125)I and (103)Pd Brachytherapy Seeds. J Res Natl Inst Stand Technol. 2016; 108(5):337-58. PMC: 4847582. DOI: 10.6028/jres.108.030. View

Yu Y, Waterman F, SUNTHARALINGAM N, Schulsinger A . Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. Int J Radiat Oncol Biol Phys. 1996; 34(3):717-25. DOI: 10.1016/0360-3016(95)02153-1. View

Melhus C, Rivard M . Approaches to calculating AAPM TG-43 brachytherapy dosimetry parameters for 137Cs, 125I, 192Ir, 103Pd, and 169Yb sources. Med Phys. 2006; 33(6):1729-37. DOI: 10.1118/1.2199987. View

S Meigooni A, Hayes J, Zhang H, Sowards K . Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE 125I brachytherapy source. Med Phys. 2002; 29(9):2152-8. DOI: 10.1118/1.1500395. View

Duggan D . Improved radial dose function estimation using current version MCNP Monte-Carlo simulation: Model 6711 and ISC3500 125I brachytherapy sources. Appl Radiat Isot. 2004; 61(6):1443-50. DOI: 10.1016/j.apradiso.2004.05.070. View

Meigooni A, Bharucha Z, Sowards K . Dosimetric characteristics of the bests double-wall 103Pd brachytherapy source. Med Phys. 2002; 28(12):2568-75. DOI: 10.1118/1.1414007. View

Older R, Synder B, Krupski T, Glembocki D, GILLENWATER J . Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol. 2001; 165(5):1590-2. View

Weaver K . Anisotropy functions for 125I and 103Pd sources. Med Phys. 1999; 25(12):2271-8. DOI: 10.1118/1.598458. View

Williamson J . Monte Carlo modeling of the transverse-axis dose distribution of the model 200 103Pd interstitial brachytherapy source. Med Phys. 2000; 27(4):643-54. DOI: 10.1118/1.598924. View

10.

S Meigooni A, Awan S, Dou K . Feasibility of calibrating elongated brachytherapy sources using a well-type ionization chamber. Med Phys. 2006; 33(11):4184-9. DOI: 10.1118/1.2358334. View

11.

Meigooni A, Sowards K, Soldano M . Dosimetric characteristics of the InterSource103 palladium brachytherapy source. Med Phys. 2000; 27(5):1093-100. DOI: 10.1118/1.598991. View

12.

Kunos C, Resnick M, Kinsella T, Ellis R . Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy. 2004; 3(2):71-7. DOI: 10.1016/j.brachy.2004.06.002. View

13.

Rivard M, Coursey B, DeWerd L, Hanson W, Huq M, Ibbott G . Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004; 31(3):633-74. DOI: 10.1118/1.1646040. View

14.

DAWSON J, Wu T, Roy T, Gu J, Kim H . Dose effects of seeds placement deviations from pre-planned positions in ultrasound guided prostate implants. Radiother Oncol. 1994; 32(3):268-70. DOI: 10.1016/0167-8140(94)90027-2. View

15.

S Meigooni A, Awan S, Rachabatthula V, Koona R . Treatment planning consideration for prostate implants with the new linear RadioCoil 103Pd brachytherapy source. J Appl Clin Med Phys. 2005; 6(3):23-36. PMC: 5723496. DOI: 10.1120/jacmp.v6i3.2097. View

16.

Awan S, S Meigooni A, Mokhberiosgouei R, Hussain M . Evaluation of TG-43 recommended 2D-anisotropy function for elongated brachytherapy sources. Med Phys. 2006; 33(11):4271-9. DOI: 10.1118/1.2357024. View

17.

Al-Qaisieh B, Carey B, Ash D, Bottomley D . The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59(2):397-9. DOI: 10.1016/j.ijrobp.2003.10.034. View

18.

Tapen E, Blasko J, Grimm P, RAGDE H, Luse R, Clifford S . Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998; 42(5):1063-7. DOI: 10.1016/s0360-3016(98)00353-8. View

19.

Nag S, Vivekanandam S, Martinez-Monge R . Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997; 39(3):667-70. DOI: 10.1016/s0360-3016(97)00342-8. View

20.

Meigooni A, Zhang H, Clark J, Rachabatthula V, Koona R . Dosimetric characteristics of the new RadioCoil 103Pd wire line source for use in permanent brachytherapy implants. Med Phys. 2004; 31(11):3095-105. DOI: 10.1118/1.1809851. View